Can Repurposed Polyvalent Vaccine Boosters (like BCG) Limit Dementia Progression by Modifying Microglial Activation Phenotypes?

Review Data

The authors have built a very comprehensive compilation of the role of microglial activation in neurodegenerative disease progression, and of ways to attenuate the microglial activation, eventually leading to a reversal of the disease phenotype. 

The readability of this review can improve if the following points are considered:

1.     Include published references that state a cause and effect relationship between increased microglial activation and increased neuronal activity

2.     Examining the synergistic effect of using psychotropics along with vaccines as therapy, to attenuate microglial activation

3.     Addressing ethico-legal and safety considerations of a randomised human trial for using a repurposed polyvalent vaccine to reduce microglial activation, especially for early onset cases. Considering that patients have died during previous studies.

4.     Elucidating the mechanism/ proposed mechanism as to how repurposed vaccination can be a safer and cheaper alternative to reduce microglial activation as opposed to either drugs or vaccination (or a combination of both)

5.     How will a repurposed polyvalent vaccine affect disease-specific oligomers, and ameliorate disease neuropathology, considering evidence of previously unsuccessful trials?

6.     Can the repurposed vaccine reverse the effects of microglial activation in patients with advanced disease progression?

7.     Can the repurposed vaccine also prevent further advancement of disease neuropathology?  OR markedly reverse disease phenotype in older subjects with existing burden? (e.g. development of amyloid plaques in case of Alzheimer’s)

If you have any questions and clarifications you can write to the journal.

Thanks,
Science Repository Team